The Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder: Results From a National Longitudinal Study

Hannah K. Knudsen; Paul M. Roman

doi:10.1016/j.jsat.2015.10.005

The Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder: Results From a National Longitudinal Study

Hannah K. Knudsen, Paul M. Roman

Behavioral Science

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

To consider how the Affordable Care Act may impact the diffusion of acamprosate, an evidence-based treatment for alcohol use disorder (AUD), the present study estimated the associations between acamprosate availability, Medicaid revenues, and private insurance revenues. Data were collected from organizational leaders of national samples of 307 specialty treatment centers in 2009-2012 and 372 treatment centers in 2011-2013. Notably, there was not a significant change in the percentage of organizations offering acamprosate over the study period. However, greater reliance on Medicaid and private insurance as sources of revenue was positively associated with the availability of acamprosate. In addition, acamprosate availability was positively associated with access to physicians and the presence of on-site primary medical care, while centers that placed greater emphasis on confrontational group therapy were significantly less likely to offer acamprosate for AUD treatment. To the extent that the ACA is expanding the number of insured individuals enrolled in Medicaid and commercial insurance sold through health insurance exchanges, this study suggests that the ACA may hold promise for expanding the availability of this EBP for AUD treatment. Future research is needed to measure whether this potential impact actually occurs within the specialty treatment system over time.

Original language	English
Pages (from-to)	62-67
Number of pages	6
Journal	Journal of Substance Abuse Treatment
Volume	62
DOIs	https://doi.org/10.1016/j.jsat.2015.10.005
State	Published - Mar 1 2016

Bibliographical note

Publisher Copyright:
© 2015 Elsevier Inc.

Funding

This research was supported by funding from the National Institute on Alcohol Abuse and Alcoholism (NIAAA Grant R01AA015974), an institute within the National Institutes of Health (NIH). Beyond this research funding, NIAAA and NIH had no further role in the research design, data analysis, or preparation of this manuscript. The content of this manuscript is solely the responsibility of the authors and does not represent the official views of the NIH or NIAAA. The authors have no conflicts of interest. This research was supported by funding from the National Institute on Alcohol Abuse and Alcoholism (NIAAA Grant R01AA015974), an institute within the National Institutes of Health (NIH). Beyond this research funding, NIAAA and NIH had no further role in the research design, data analysis, or preparation of this manuscript. The content of this manuscript is solely the responsibility of the authors and does not represent the official views of the NIH or NIAAA. The authors have no conflicts of interest.

Funders	Funder number
National Institutes of Health (NIH)
National Institute on Drug Abuse	R37DA013110
National Institute on Alcohol Abuse and Alcoholism	R01AA015974

Keywords

Acamprosate
Affordable care act
Alcohol use disorder
Health reform
Insurance
Medicaid

ASJC Scopus subject areas

Psychiatric Mental Health
Medicine (miscellaneous)
Clinical Psychology
Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jsat.2015.10.005

Cite this

@article{1d32e55795bb438da242c88aeeaaf34b,

title = "The Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder: Results From a National Longitudinal Study",

abstract = "To consider how the Affordable Care Act may impact the diffusion of acamprosate, an evidence-based treatment for alcohol use disorder (AUD), the present study estimated the associations between acamprosate availability, Medicaid revenues, and private insurance revenues. Data were collected from organizational leaders of national samples of 307 specialty treatment centers in 2009-2012 and 372 treatment centers in 2011-2013. Notably, there was not a significant change in the percentage of organizations offering acamprosate over the study period. However, greater reliance on Medicaid and private insurance as sources of revenue was positively associated with the availability of acamprosate. In addition, acamprosate availability was positively associated with access to physicians and the presence of on-site primary medical care, while centers that placed greater emphasis on confrontational group therapy were significantly less likely to offer acamprosate for AUD treatment. To the extent that the ACA is expanding the number of insured individuals enrolled in Medicaid and commercial insurance sold through health insurance exchanges, this study suggests that the ACA may hold promise for expanding the availability of this EBP for AUD treatment. Future research is needed to measure whether this potential impact actually occurs within the specialty treatment system over time.",

keywords = "Acamprosate, Affordable care act, Alcohol use disorder, Health reform, Insurance, Medicaid",

author = "Knudsen, {Hannah K.} and Roman, {Paul M.}",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2016",

month = mar,

day = "1",

doi = "10.1016/j.jsat.2015.10.005",

language = "English",

volume = "62",

pages = "62--67",

}

TY - JOUR

T1 - The Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder

T2 - Results From a National Longitudinal Study

AU - Knudsen, Hannah K.

AU - Roman, Paul M.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - To consider how the Affordable Care Act may impact the diffusion of acamprosate, an evidence-based treatment for alcohol use disorder (AUD), the present study estimated the associations between acamprosate availability, Medicaid revenues, and private insurance revenues. Data were collected from organizational leaders of national samples of 307 specialty treatment centers in 2009-2012 and 372 treatment centers in 2011-2013. Notably, there was not a significant change in the percentage of organizations offering acamprosate over the study period. However, greater reliance on Medicaid and private insurance as sources of revenue was positively associated with the availability of acamprosate. In addition, acamprosate availability was positively associated with access to physicians and the presence of on-site primary medical care, while centers that placed greater emphasis on confrontational group therapy were significantly less likely to offer acamprosate for AUD treatment. To the extent that the ACA is expanding the number of insured individuals enrolled in Medicaid and commercial insurance sold through health insurance exchanges, this study suggests that the ACA may hold promise for expanding the availability of this EBP for AUD treatment. Future research is needed to measure whether this potential impact actually occurs within the specialty treatment system over time.

AB - To consider how the Affordable Care Act may impact the diffusion of acamprosate, an evidence-based treatment for alcohol use disorder (AUD), the present study estimated the associations between acamprosate availability, Medicaid revenues, and private insurance revenues. Data were collected from organizational leaders of national samples of 307 specialty treatment centers in 2009-2012 and 372 treatment centers in 2011-2013. Notably, there was not a significant change in the percentage of organizations offering acamprosate over the study period. However, greater reliance on Medicaid and private insurance as sources of revenue was positively associated with the availability of acamprosate. In addition, acamprosate availability was positively associated with access to physicians and the presence of on-site primary medical care, while centers that placed greater emphasis on confrontational group therapy were significantly less likely to offer acamprosate for AUD treatment. To the extent that the ACA is expanding the number of insured individuals enrolled in Medicaid and commercial insurance sold through health insurance exchanges, this study suggests that the ACA may hold promise for expanding the availability of this EBP for AUD treatment. Future research is needed to measure whether this potential impact actually occurs within the specialty treatment system over time.

KW - Acamprosate

KW - Affordable care act

KW - Alcohol use disorder

KW - Health reform

KW - Insurance

KW - Medicaid

UR - http://www.scopus.com/inward/record.url?scp=84955627963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955627963&partnerID=8YFLogxK

U2 - 10.1016/j.jsat.2015.10.005

DO - 10.1016/j.jsat.2015.10.005

M3 - Article

C2 - 26689318

AN - SCOPUS:84955627963

SN - 0740-5472

VL - 62

SP - 62

EP - 67

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

ER -

The Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder: Results From a National Longitudinal Study

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this